ATAI LIFE SCIENCES
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.
ATAI LIFE SCIENCES
Industry:
Biotechnology Health Care Life Science Mental Health Therapeutics
Founded:
2018-01-01
Status:
Active
Contact:
+49 (0) 89 2153 9035
Email Addresses:
[email protected]
Total Funding:
522.1 M USD
Technology used in webpage:
IPv6 Person Schema Facebook Sharer Gravatar Profiles U.S. Server Location Pinterest Akamai Hosted WordPress 5.9
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
COMPASS Pathways
Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
Garuda Therapeutics
Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat severe and life-threatening diseases.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-04-07 | Psyber | Psyber acquired by ATAI Life Sciences | N/A |
| 2021-01-12 | Recognify Life Sciences | Recognify Life Sciences acquired by ATAI Life Sciences | N/A |
| 2019-01-03 | Perception Neuroscience | Perception Neuroscience acquired by ATAI Life Sciences | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - ATAI Life Sciences
GrayBella Capital
GrayBella Capital investment in Convertible Note - ATAI Life Sciences
Talent Resources Ventures
Talent Resources Ventures investment in Funding Round - ATAI Life Sciences
Infinitas Capital
Infinitas Capital investment in Series D - ATAI Life Sciences
What If Ventures
What If Ventures investment in Series D - ATAI Life Sciences
Alpha Wave Global
Alpha Wave Global investment in Series D - ATAI Life Sciences
Arda Kara
Arda Kara investment in Series D - ATAI Life Sciences
Subversive Capital
Subversive Capital investment in Series D - ATAI Life Sciences
Presight Capital
Presight Capital investment in Series D - ATAI Life Sciences
Korify Capital
Korify Capital investment in Series D - ATAI Life Sciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-01-04 | Beckley Psytech | ATAI Life Sciences investment in Corporate Round - Beckley Psytech | 40 M USD |
| 2024-01-04 | Beckley Psytech | ATAI Life Sciences investment in Secondary Market - Beckley Psytech | 10 M USD |
| 2023-08-31 | IntelGenX | ATAI Life Sciences investment in Post-IPO Equity - IntelGenX | 3 M CAD |
| 2023-01-09 | IntelGenX | ATAI Life Sciences investment in Post-IPO Debt - IntelGenX | 3 M USD |
| 2022-02-01 | IntelGenX | ATAI Life Sciences investment in Post-IPO Debt - IntelGenX | 3 M USD |
| 2021-03-15 | IntelGenX | ATAI Life Sciences investment in Post-IPO Equity - IntelGenX | 12.35 M USD |
| 2021-03-15 | IntelGenX | ATAI Life Sciences investment in Post-IPO Debt - IntelGenX | 2 M USD |
| 2020-04-27 | COMPASS Pathways | ATAI Life Sciences investment in Series B - COMPASS Pathways | 80 M USD |
| 2019-04-24 | Innoplexus | ATAI Life Sciences investment in Series C - Innoplexus | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2024-02-06 | Atai Life Sciences Names Anne Johnson CFO |
More informations about "ATAI Life Sciences"
Our Approach - atai Life Sciences
Atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Berlin. Our vision is to heal mental health disorders so that …See details»
Why federal agencies say now is the time to explore psychedelics
ATAI Life Sciences - Crunchbase Investor Profile & Investments
ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany. Read More. Lists Featuring This Company. Edit Lists Featuring This Company Section. Therapeutics …See details»
ATAI Life Sciences - Psychedelic Science Review
Dec 19, 2018 ATAI Life Sciences Its holdings’ foci range from drug discovery to drug development to enabling technologies, including novel administration methods and digital …See details»
Company Company Overview Overview March 2023 - ATAI Life …
“Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries, unless the context otherwise requires. This presentation may include forward-looking statements. All statements …See details»
atai Life Sciences - LinkedIn
Atai Life Sciences | 25,266 followers on LinkedIn. Healing mental health disorders so that everyone, everywhere can live a more fulfilled life. | Who we are: atai is a biopharmaceutical …See details»
Peter Thiel-Backed Psychedelics Company Gets FDA Approval To …
Jan 12, 2022 The U.S. Food and Drug Administration has authorized German psychedelics startup Atai Life Sciences to conduct a clinical trial on a nonpsychedelic form of ketamine for …See details»
atai Life Sciences - LinkedIn
Atai Life Sciences | 27,280 followers on LinkedIn. Healing mental health disorders so that everyone, everywhere can live a more fulfilled life. | Who we are: atai is a biopharmaceutical company ...See details»
A 36-year-old CEO saw how psychedelics treated his …
Dec 5, 2022 Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.See details»
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL …
NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the …See details»
Investor Relations - ATAI Life Sciences N.V.
Sep 4, 2024 atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. We founded atai in 2018 as a response to …See details»
Atai impact - atai Life Sciences
Its mission is an extension of atai Life Sciences’ vision: to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Our Approach. Supporting and …See details»
ATAI Life Sciences - Funding, Financials, Valuation & Investors
ATAI Life Sciences is registered under the ticker NASDAQ:ATAI . Their stock opened with $15.00 in its Jun 17, 2021 IPO. Stock Symbol NASDAQ:ATAI ; Valuation at IPO $2.3B; Money Raised …See details»
ATAI Life Sciences - Investments, Portfolio & Company Exits
ATAI Life Sciences 's most notable exits include COMPASS Pathways and IntelGenX. ATAI Life Sciences has acquired 4 organizations. Their most recent acquisition was IntelGenX on Sep …See details»
atai Life Sciences Reports First Quarter 2022 Financial Results and ...
May 16, 2022 Net income (loss) per share attributable to ATAI Life Sciences N.V. stockholders– diluted $ (0.24) $ 0.01: Weighted average common shares outstanding attributable to ATAI …See details»
Atai Life Sciences N.V. (ATAI) - Stock Analysis
Nov 22, 2024 Financial Performance. In 2023, Atai Life Sciences's revenue was $314,000, an increase of 34.76% compared to the previous year's $233,000. Losses were -$40.22 million, …See details»
atai Life Sciences Reports Fourth Quarter and Full Year 2022 …
NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of …See details»
atai Life Sciences Reports Fourth Quarter and Full Year 2022 …
Mar 24, 2023 atai Life Sciences . Fri, Mar 24, 2023, 6:59 AM 15 min read. In This Article: ATAI . atai’s development candidates, such as RL-007 and GRX-917, all represent significant …See details»
Positive Outlook for ATAI Life Sciences Amidst Upcoming Clinical …
Aug 16, 2024 Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on ATAI Life Sciences (ATAI – Research Report). The associated price target is $6.00. The …See details»